Precigen (PGEN) Non Operating Income (2012 - 2026)
Precigen (PGEN) posted quarterly Non Operating Income of -$1.9 million for Q1 2026, up 93.87% year-over-year from -$998100.6 in Q1 2025, and down 5.33% quarter-over-quarter from -$1.8 million in Q4 2025.
Analysis
Precigen (PGEN) Non Operating Income (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Non Operating Income for 15 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 93.87% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$110.5 million (down 338.55% YoY), while the FY2025 annual figure was -$140.1 million, down 2101.6% from the prior year.
- Non Operating Income eased to -$1.9 million in Q1 2026 per PGEN's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $8.7 million in Q4 2024 and bottomed at -$111.9 million in Q3 2025.
- Historically, Non Operating Income has averaged -$8.0 million across 5 years, with a median of -$372000.0 in 2022.
- On a YoY basis, Non Operating Income climbed as much as 1323.61% in 2025 and fell as far as 5007.78% in 2025.
- Precigen's Non Operating Income stood at -$372000.0 in 2022, then jumped by 324.73% to $836000.0 in 2023, then jumped by 940.91% to $8.7 million in 2024, then plunged by 121.11% to -$1.8 million in 2025, then retreated by 5.33% to -$1.9 million in 2026.
- Business Quant data shows PGEN's Non Operating Income at -$1.9 million in Q1 2026, -$1.8 million in Q4 2025, and -$111.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | -2.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.57 Mn |
| Mar 31, 2026 | -1.94 Mn |
| Dec 31, 2025 | -1.84 Mn |
| Sep 30, 2025 | -111.86 Mn |
| Jun 30, 2025 | 5.13 Mn |
| Mar 31, 2025 | -31.56 Mn |
| Dec 31, 2024 | 8.70 Mn |
| Sep 30, 2024 | -2.70 Mn |
| Jun 30, 2024 | 360,000.00 |
| Mar 31, 2024 | 643,000.00 |
| Dec 31, 2023 | 836,000.00 |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 736,000.00 |
| Mar 31, 2023 | 689,000.00 |
| Dec 31, 2022 | -372,000.00 |
| Sep 30, 2022 | -942,000.00 |
| Jun 30, 2022 | -1.99 Mn |
| Mar 31, 2022 | -1.80 Mn |
| Dec 31, 2021 | -4.81 Mn |
| Sep 30, 2021 | -4.85 Mn |